JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ — Celltrion today announced the U.S. Food and Drug Administration (FDA) approved Omlyclo® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with Xolair®…Original Article
FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair
